Hepatotoxicity of antibacterials: Pathomechanisms and clinical

Infection

Volumn 38, Issue 1, 2010, Pages 3-11

  Leitner, J M ^a   Graninger, W ^a   Thalhammer, F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTINUCLEAR ANTIBODY; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; IMMUNOGLOBULIN; ISONIAZID; KETOCONAZOLE; MACROLIDE; MINOCYCLINE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXACILLIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; SULFONAMIDE; TERBINAFINE; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BILE DUCT DISEASE; BILIARY CIRRHOSIS; CHOLESTASIS; CHOLESTATIC HEPATITIS; DERMATITIS; DISEASE SEVERITY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EOSINOPHILIA; FATTY LIVER; FEVER; HEPATITIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER GRANULOMA; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MORTALITY; NONHUMAN; PATIENT SAFETY; REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXICOGENETICS; VANISHING BILE DUCT SYNDROME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER;

EID: 77549083833     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-009-9179-z     Document Type: Review

References (72)

1. B. Hughes 2008 Industry concern over EU hepatotoxicity guidance Nat Rev Drug Discov 7 719 10.1038/nrd2677 1:CAS:528:DC%2BD1cXhtVGgtL%2FO 19172685
2. Y. Meier M. Cavallaro M. Roos C. Pauli-Magnus G. Folkers P.J. Meier K. Fattinger 2005 Incidence of drug-induced liver injury in medical inpatients Eur J Clin Pharmacol 61 135 143 10.1007/s00228-004-0888-z 15726344 (Pubitemid 40674746)
3. H.U. Marschall M. Wagner G. Zollner M. Trauner 2007 Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors Mol Pharm 4 895 910 10.1021/mp060133c 1:CAS:528:DC%2BD2sXhtlSkurjO 18001054
4. H.J. Zimmerman 2000 Drug-induced liver disease Clin Liver Dis 4 73 96vi 10.1016/S1089-3261(05)70097-0 1:STN:280:DC%2BD3MvitFOquw%3D%3D 11232192
5. J.E. Polson 2007 Hepatotoxicity due to antibiotics Clin Liver Dis 11 549 561vi 10.1016/j.cld.2007.06.009 17723919 (Pubitemid 47302349)
6. M.A. Steele R.F. Burk R.M. DesPrez 1991 Toxic hepatitis with isoniazid and rifampin. A meta-analysis Chest 99 465 471 10.1378/chest.99.2.465 1:STN:280:DyaK3M7hsVCisA%3D%3D 1824929
7. J.J. Saukkonen D.L. Cohn R.M. Jasmer S. Schenker J.A. Jereb C.M. Nolan C.A. Peloquin F.M. Gordin D. Nunes D.B. Strader J. Bernardo R. Venkataramanan T.R. Sterling 2006 An official ATS statement: hepatotoxicity of antituberculosis therapy Am J Respir Crit Care Med 174 935 952 10.1164/rccm.200510-1666ST 1:CAS:528:DC%2BD28Xht1SgtLnJ 17021358 (Pubitemid 44564795)
8. W.W. Yew C.C. Leung 2006 Antituberculosis drugs and hepatotoxicity Respirology 11 699 707 10.1111/j.1440-1843.2006.00941.x 17052297 (Pubitemid 44581433)
9. M. Trauner M. Wagner P. Fickert G. Zollner 2005 Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis J Clin Gastroenterol 39 S111 S124 10.1097/01.mcg. 0000155551.37266.26 15758646
10. M. Wagner G. Zollner M. Trauner 2009 New molecular insights into the mechanisms of cholestasis J Hepatol 51 565 580 10.1016/j.jhep.2009.05.012 1:CAS:528:DC%2BD1MXpsFyhs7g%3D 19595470
11. G. Zollner M. Trauner 2008 Mechanisms of cholestasis Clin Liver Dis 12 1 26vii 10.1016/j.cld.2007.11.010 18242495 (Pubitemid 351163143)
12. M. Fuchs A.J. Sanyal 2008 Sepsis and cholestasis Clin Liver Dis 12 151 172ix 10.1016/j.cld.2007.11.002 18242502 (Pubitemid 351163137)
13. M. Thiim L.S. Friedman 2003 Hepatotoxicity of antibiotics and antifungals Clin Liver Dis 7 381 399vi-vii 10.1016/S1089-3261(03)00021-7 12879990
14. W.M. Lee 2003 Drug-induced hepatotoxicity N Engl J Med 349 474 485 10.1056/NEJMra021844 1:CAS:528:DC%2BD3sXms1Ogs78%3D 12890847 (Pubitemid 36910027)
15. P.B. Watkins L.B. Seeff 2006 Drug-induced liver injury: summary of a single topic clinical research conference Hepatology 43 618 631 10.1002/hep.21095 16496329
16. E. Björnsson R. Olsson 2005 Outcome and prognostic markers in severe drug-induced liver disease Hepatology 42 481 489 10.1002/hep.20800 16025496 (Pubitemid 41061102)
17. N. Chalasani R.J. Fontana H.L. Bonkovsky P.B. Watkins T. Davern J. Serrano H. Yang J. Rochon 2008 Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States Gastroenterology 135 1924 1934 10.1053/j.gastro.2008.09.011 18955056
18. R.J. Andrade M.I. Lucena M.C. Fernández G. Pelaez K. Pachkoria E. García-Ruiz B. García-Muñoz R. González-Grande A. Pizarro J.A. Durán M. Jiménez L. Rodrigo M. Romero-Gomez J.M. Navarro R. Planas J. Costa A. Borras A. Soler J. Salmerón R. Martin-Vivaldi 2005 Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period Gastroenterology 129 512 521 16083708
19. M. Müller 2003 Pharmacogenomics and drug response Int J Clin Pharmacol Ther 41 231 240 12816175
20. S.S. Lee J.T. Buters T. Pineau P. Fernández-Salguero F.J. González 1996 Role of CYP2E1 in the hepatotoxicity of acetaminophen J Biol Chem 271 12063 12067 10.1074/jbc.271.20.12063 1:CAS:528:DyaK28XjtV2ksL8%3D 8662637 (Pubitemid 26157285)
21. Y.S. Huang H.D. Chern W.J. Su J.C. Wu S.C. Chang C.H. Chiang F.Y. Chang S.D. Lee 2003 Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis Hepatology 37 924 930 10.1053/jhep.2003.50144 1:CAS:528:DC%2BD3sXjt1Wlurc%3D 12668988 (Pubitemid 36397406)
22. Y.S. Huang H.D. Chern W.J. Su J.C. Wu S.L. Lai S.Y. Yang F.Y. Chang S.D. Lee 2002 Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis Hepatology 35 883 889 10.1053/jhep.2002.32102 1:CAS:528:DC%2BD38XjtFSksLw%3D 11915035 (Pubitemid 34258383)
23. J.R. Mitchell H.J. Zimmerman K.G. Ishak U.P. Thorgeirsson J.A. Timbrell W.R. Snodgrass S.D. Nelson 1976 Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis Ann Intern Med 84 181 192 1:STN:280:DyaE287jsVGgsw%3D%3D 766682
24. A. Enomoto K. Itoh E. Nagayoshi J. Haruta T. Kimura T. O'Connor T. Harada M. Yamamoto 2001 High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes Toxicol Sci 59 169 177 10.1093/toxsci/59.1.169 1:CAS:528:DC%2BD3MXlsl2itA%3D%3D 11134556 (Pubitemid 32117993)
25. J. O'Donohue K.A. Oien P. Donaldson J. Underhill M. Clare R.N. MacSween P.R. Mills 2000 Co-amoxiclav jaundice: clinical and histological features and HLA class II association Gut 47 717 720 10.1136/gut.47.5.717 11034591 (Pubitemid 30809053)
26. S. Mallal D. Nolan C. Witt G. Masel A.M. Martin C. Moore D. Sayer A. Castley C. Mamotte D. Maxwell I. James F.T. Christiansen 2002 Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 727 732 10.1016/S0140-6736(02)07873-X 1:CAS:528:DC%2BD38XhvVWhsbY%3D 11888582 (Pubitemid 34215071)
27. E. Fréneaux G. Labbe P. Letteron D. The Le C. Degott J. Genève D. Larrey D. Pessayre 1988 Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic Hepatology 8 1056 1062 10.1002/hep.1840080513 3417225 (Pubitemid 18236603)
28. R.L. Peters H.A. Edmondson W.P. Mikkelsen D. Tatter 1967 Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases Am J Surg 113 622 632 10.1016/0002-9610(67)90308-X 1:STN:280: DyaF2s7ivVGjtw%3D%3D 6021433
29. J.C. Schultz J.S. Adamson Jr W.W. Workman T.D. Norman 1963 Fatal liver disease after intravenous administration of tetracycline in high dosage N Engl J Med 269 999 1004 1:CAS:528:DyaF2cXksFOiur8%3D 14059734
30. E. Björnsson J. Lindberg R. Olsson 1997 Liver reactions to oral low-dose tetracyclines Scand J Gastroenterol 32 390 395 10.3109/ 00365529709007690 9140164
31. J.L. Carson B.L. Strom A. Duff A. Gupta M. Shaw F.E. Lundin K. Das 1993 Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines Ann Intern Med 119 576 583 1:STN:280:DyaK3szntVOrtQ%3D%3D 8363168
32. A. Gough S. Chapman K. Wagstaff P. Emery E. Elias 1996 Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome BMJ 312 169 172 1:CAS:528:DyaK28Xhtlyms7o%3D 8563540
33. N.S. Goldstein N. Bayati A.L. Silverman S.C. Gordon 2000 Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis Am J Clin Pathol 114 591 598 10.1309/KV2J-VX6Q-L95V- VDE4 1:STN:280:DC%2BD3cvns1emtQ%3D%3D 11026106 (Pubitemid 33044399)
34. J.P. Boudreaux D.H. Hayes S. Mizrahi J. Hussey F. Regenstein L. Balart 1993 Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity Transplant Proc 25 1873 1:STN:280:DyaK3s3isleltw%3D%3D 8470208
35. T. Pohle J. Menzel W. Domschke 2000 Minocycline and fulminant hepatic failure necessitating liver transplantation Am J Gastroenterol 95 560 561 1:STN:280:DC%2BD3c7kvVaitw%3D%3D 10685779
36. J.E. Losanoff J.M. Holder-Murray E.B. Ahmed A.B. Cochrane G. Testa J.M. Millis 2007 Minocycline toxicity requiring liver transplant Dig Dis Sci 52 3242 3244 10.1007/s10620-006-9550-1 17404879 (Pubitemid 47512515)
37. P.F. D'Arcy 1985 Nitrofurantoin Drug Intell Clin Pharm 19 540 547 3896715
38. C.A. Dujovne C.H. Chan H.J. Zimmerman 1967 Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole N Engl J Med 277 785 788 1:STN:280:DyaF2s3mtFalug%3D%3D 6046676
39. M.J. Ilario J.E. Ruiz C.A. Axiotis 2000 Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim-sulfamethoxazole Arch Pathol Lab Med 124 1800 1803 1:STN:280:DC%2BD3M%2FpsVyqtQ%3D%3D 11100060
40. G. Kouklakis A. Mpoumponaris P. Zezos J. Moschos A. Koulaouzidis A. Nakos A. Pehlivanidis M. Iosiphidis E. Molyvas N. Nikolaidis 2007 Cholestatic hepatitis with severe systemic reactions induced by trimethoprim- sulfamethoxazole Ann Hepatol 6 63 65 1:STN:280:DC%2BD2s7htFChtg%3D%3D 17297432
41. H.P. Lazar R.L. Murphy J.P. Phair 1985 Fansidar and hepatic granulomas Ann Intern Med 102 722 1:STN:280:DyaL2M7nt12msw%3D%3D 3985527
42. B.J. Zitelli J. Alexander S. Taylor K.D. Miller D.L. Howrie J.N. Kuritsky T.H. Perez D.H. Van Thiel 1987 Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar) Ann Intern Med 106 393 395 1:STN:280:DyaL2s7is1WntQ%3D%3D 2949680
43. B.G. Junghanss 1998 Increase in transaminases in HIV infection. Toxic liver cell damage with trimethoprim/sulfamethoxazole administration in HIV infection Praxis (Bern 1994) 87 361 362 1:STN:280:DyaK1c3gslCmtw%3D%3D
44. C. Wenisch R. Krause P. Fladerer I. El Menjawi E. Pohanka 2000 Acute rhabdomyolysis after atorvastatin and fusidic acid therapy Am J Med 109 78 10.1016/S0002-9343(00)00367-3 1:STN:280:DC%2BD3cvjtFyqtA%3D%3D 10991749
45. K. Christiansen 1999 Fusidic acid adverse drug reactions Int J Antimicrob Agents 12 [Suppl2] S3 S9 10.1016/S0924-8579(98)00068-5 1:CAS:528: DyaK1MXntlOhtb4%3D 10528781
46. K.A. Bode M.G. Donner I. Leier D. Keppler 2002 Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate Biochem Pharmacol 64 151 158 10.1016/S0006-2952(02)01015-8 1:CAS:528: DC%2BD38XltFSqsL0%3D 12106615 (Pubitemid 34775185)
47. E.J. Forget D. Menzies 2006 Adverse reactions to first-line antituberculosis drugs Expert Opin Drug Saf 5 231 249 10.1517/14740338.5.2.231 1:CAS:528:DC%2BD28XhvVKnsbo%3D 16503745 (Pubitemid 43379622)
48. D.L. Brummer 1971 Isoniazid and liver disease Ann Intern Med 75 643 644 1:STN:280:DyaE38%2FgtlSlug%3D%3D 5094080
49. W.C. Maddrey 1981 Isoniazid-induced liver disease Semin Liver Dis 1 129 133 10.1055/s-2008-1040725 1:STN:280:DyaL383nslamsg%3D%3D 7347016
50. A.J. Pugh A.J. Barve K. Falkner M. Patel C.J. McClain 2009 Drug-induced hepatotoxicity or drug-induced liver injury Clin Liver Dis 13 277 294 10.1016/j.cld.2009.02.008 19442919
51. Centers for Disease ControlPrevention 2003 Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003 MMWR Morb Mortal Wkly Rep 52 735 739
52. B. Knobel G. Buyanowsky M. Dan L. Zaidel 1997 Pyrazinamide-induced granulomatous hepatitis J Clin Gastroenterol 24 264 266 10.1097/00004836- 199706000-00019 1:STN:280:DyaK2szps1KqsA%3D%3D 9252856 (Pubitemid 27310602)
53. L.E. Derby H. Jick D.A. Henry A.D. Dean 1993 Erythromycin-associated cholestatic hepatitis Med J Aust 158 600 602 1:STN:280:DyaK3s3ktFSqsg%3D%3D 8479375
54. P. Braun 1969 Hepatotoxicity of erythromycin J Infect Dis 119 300 306 1:STN:280:DyaF1M7ms1ygsg%3D%3D 4888905
55. S. Chandrupatla A.J. Demetris M. Rabinovitz 2002 Azithromycin-induced intrahepatic cholestasis Dig Dis Sci 47 2186 2188 10.1023/A:1020170807742 12395890 (Pubitemid 35205292)
56. K. Christopher P.A. Hyatt C. Horkan P.C. Yodice 2002 Clarithromycin use preceding fulminant hepatic failure Am J Gastroenterol 97 489 490 11866297
57. A.D. Brinker R.T. Wassel J. Lyndly J. Serrano M. Avigan W.M. Lee L.B. Seeff 2009 Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases Hepatology 49 250 257 10.1002/hep.22620 19085949
58. D.B. Ross 2007 The FDA and the case of Ketek N Engl J Med 356 1601 1604 10.1056/NEJMp078032 1:CAS:528:DC%2BD2sXksFCgtb4%3D 17442902 (Pubitemid 46631668)
59. V.J. Navarro J.R. Senior 2006 Drug-related hepatotoxicity N Engl J Med 354 731 739 10.1056/NEJMra052270 1:CAS:528:DC%2BD28XhsVWrtr8%3D 16481640 (Pubitemid 43247143)
60. S.H. Hussaini C.S. O'Brien E.J. Despott H.R. Dalton 2007 Antibiotic therapy: a major cause of drug-induced jaundice in southwest England Eur J Gastroenterol Hepatol 19 15 20 10.1097/01.meg.0000250581.77865.68 1:CAS:528:DC%2BD2sXhvFWitw%3D%3D 17206072 (Pubitemid 46066863)
61. R.J. Fontana A.O. Shakil J.K. Greenson I. Boyd W.M. Lee 2005 Acute liver failure due to amoxicillin and amoxicillin/clavulanate Dig Dis Sci 50 1785 1790 10.1007/s10620-005-2938-5 16187174 (Pubitemid 41413891)
62. U. Gresser 2001 Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature Eur J Med Res 6 139 149 1:CAS:528:DC%2BD3MXks1KmtL4%3D 11309226
63. L.A. García Rodríguez B.H. Stricker H.J. Zimmerman 1996 Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid Arch Intern Med 156 1327 1332 10.1001/archinte.156.12.1327 8651842 (Pubitemid 26196892)
64. F. Salvo G. Polimeni U. Moretti A. Conforti R. Leone O. Leoni D. Motola G. Dusi A.P. Caputi 2007 Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy J Antimicrob Chemother 60 121 126 10.1093/jac/dkm111 1:CAS:528: DC%2BD2sXot1ertr8%3D 17449881 (Pubitemid 47078716)
65. R. Leone M. Venegoni D. Motola U. Moretti V. Piazzetta A. Cocci D. Resi F. Mozzo G. Velo L. Burzilleri N. Montanaro A. Conforti 2003 Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions Drug Saf 26 109 120 10.2165/00002018-200326020-00004 1:CAS:528:DC%2BD3sXhs1yqsbo%3D 12534327 (Pubitemid 36188561)
66. E. Rubinstein 2001 History of quinolones and their side effects Chemotherapy 47 [Suppl3] 3 8 10.1159/000057838 1:CAS:528:DC%2BD3MXnsV2qtrc%3D 11549783
67. Drug Committee of the German Medical Association: hepatotoxicity of fluoroquinolones. Deutsches Ärzteblatt 2002; A 3490.
68. D.M. Shlaes R.C. Moellering 2008 Telithromycin and the FDA: implications for the future Lancet Infect Dis 8 83 85 10.1016/S1473-3099(08)70002-1 18222155
69. F. Van Bambeke P.M. Tulkens 2009 Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes Drug Saf 32 359 378 10.2165/00002018-200932050-00001 19419232
70. D. Motola A. Vargiu R. Leone A. Cocci F. Salvo B. Ros I. Meneghelli M. Venegoni P.M. Cutroneo A. Vaccheri G. Velo N. Montanaro 2007 Hepatic adverse drug reactions: a case/non-case study in Italy Eur J Clin Pharmacol 63 73 79 10.1007/s00228-006-0222-z 17119945 (Pubitemid 46025476)
71. L.E. Derby H. Jick D.A. Henry A.D. Dean 1993 Cholestatic hepatitis associated with flucloxacillin Med J Aust 158 596 600 1:STN:280: DyaK3s3ktFSruw%3D%3D 8479374
72. C. Carbon 2001 Levofloxacin adverse effects, data from clinical trials and pharmacovigilance Therapie 56 35 40 1:STN:280:DC%2BD3M3jtVCjsw%3D%3D 11322015